Chicago, ILNCT07464925Now EnrollingIRB Ready

Glioblastoma Multiforme of Brain Clinical Trial in Chicago, IL

Access cutting-edge glioblastoma multiforme of brain treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Tetragon Biosciences Ltd

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access glioblastoma multiforme of brain specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related glioblastoma multiforme of brain treatment provided free

Apply for This Chicago Location

Check if you qualify for this glioblastoma multiforme of brain clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Glioblastoma Multiforme of Brain Study in Chicago

This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic profiles and preliminary clinical activity in participants with a high grade diffuse glioma that progressed during or recurred after prior standard of care therapies or investigational therapies as clinically indicated. Patients will be treated daily with GLIX1 capsules until disease progression or unacceptable safety.

Sponsor: Tetragon Biosciences Ltd

Who Can Participate

Inclusion Criteria

Adult patients aged ≥18 years at the time of informed consent
Participants must have histologically confirmed Grade 3 or Grade 4 glioma
Recurrent or progressive disease
A maximum of two prior treatment lines
Interval of at least 3 months since the last day off of radiotherapy, unless tumor progression and index lesion is outside the prior radiation field.
Interval since last dose of systemic therapy and Baseline MRI of ≥28 days, except:
for nitrosoureas (e.g., lomustine, carmustine, fotemustine): 42 days (6 weeks)
for monoclonal antibodies: 42 days (6 weeks)
for small molecules, 4 weeks or at least 5 half-lives (whatever is longer)
Recovered from all toxicities from prior treatments to Grade 1 or less by NCI CTCAE v6.0:
Participants receiving corticosteroids must be on a stable or decreasing dose of ≤6 mg daily dexamethasone (or ≤40 mg prednisone) for the 7 days prior to the start of study treatment.
Participants with seizures must be adequately controlled on a stable regimen of anti-epileptic drugs.
Adequate performance status: Eastern Cooperative Oncology Group (ECOG) 0 or 1.
Ability to swallow tablets or capsules.
Adequate hematological, liver and renal function.
Women of childbearing potential must have a negative serum pregnancy test result within 7 days prior to first dosing. Women must use a highly effective form of contraception (with Pearl Index \<1%) for the duration of the study and for at least 3 months after the last dose of study medication.
Men with partners of childbearing potential must be willing to use condoms in combination with a second effective method of contraception by the partner during the study and for at least 3 months after the last dose of study medication. Main

Exclusion Criteria

Known contraindication for gadolinium (Gd) based, contrast-enhanced MRI
Prior history of another invasive malignancy unless a complete remission was achieved at least 3 years prior to enrolment AND no additional therapy is required during the study period, except for anti-estrogen or androgen therapy and/or bisphosphonates or denosumab.
Participants with known active or uncontrolled infection, and/or unexplained fever \>38°C in the 3 days prior to the start of study treatment.
Major non-tumor related surgical procedure or significant traumatic injury within 28 days prior to signing of consent.
Receiving any investigational products (defined as treatment for which there is currently no regulatory authority-approved indication) within 4 weeks or 5 half-lives (whichever is the longest) prior to Baseline MRI.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07464925) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Glioblastoma Multiforme of Brain Treatment Options in Chicago, IL

If you're searching for glioblastoma multiforme of brain treatment options in Chicago, IL, this clinical trial (NCT07464925) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma multiforme of brain specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all glioblastoma multiforme of brain clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Chicago, IL

See all brain cancer clinical trials recruiting in Chicago — not just this study.

Browse Brain Cancer Trials in Chicago →

Browse More Trials by Condition

Brain Cancer TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL